Please assess the completion status of the following clinical trial:

Trial Title: PF-06741086 Long-term Treatment in Severe Hemophilia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Severe hemophilia A or B (Factor VIII or Factor IX activity ≤ 1%)~* Subjects enrolled as Factor VIII or Factor IX inhibitor patients must have a positive inhibitor test result (above the upper limit of normal) at the local laboratory and must receive a bypass agent as primary treatment for bleeding episodes.~* Episodic (on-demand) treatment regimen prior to screening~* At least 6 acute bleeding episodes during the 6-month period prior to screening~Exclusion Criteria:~* Known coronary artery, thrombotic, or ischemic disease~* Concomitant treatment with activated prothrombin complex concentrate

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- PF-06741086 (Cohort 1) (Type: EXPERIMENTAL): None
- PF-06741086 (Cohort 2) (Type: EXPERIMENTAL): None
- PF-06741086 (Cohort 3) (Type: EXPERIMENTAL): None
- PF-06741086 (Cohort 4) (Type: EXPERIMENTAL): None
- PF-06741086 (Cohort 5) (Type: EXPERIMENTAL): None
- PF-06741086 (Cohort 6) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).